This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: insulin

Older antidiabetic drugs

March 2018 doi:10.5837/bjc.2018.007

Older antidiabetic drugs

Emma Johns, Gerry McKay, Miles Fisher

Abstract

(more…)

| Full text
In brief

June 2013 Br J Cardiol 2013;20:56

In brief

BJCardio Staff

Abstract

ESC backs regulations for medical devices The European Society of Cardiology has said in a position paper that it welcomes the European Commission’s (EC) proposals for a new Regulation to govern the evaluation and approval of medical devices in Europe as an important step towards improving patient safety. The EC proposal document is available at http://ec.europa.eu/health/medical-devices/documents/revision/index_en.htm New risk analysis scoring system A new risk scoring system, based on the SMART study, allows doctors to determine more accurately the risk of cardiovascular disease patients developing a new event, such as heart attack or str

| Full text
Drugs for diabetes: part 7 insulin

October 2011 Br J Cardiol 2011;18:224-228 doi:10.5837/bjc.2011.003

Drugs for diabetes: part 7 insulin

Nicholas D Barwell, Gerard A McKay, Miles Fisher

Abstract

Introduction Treatment with insulin is essential for a good prognosis in patients with type 1 diabetes, and it is a potent hypoglycaemic agent in patients with type 2 diabetes. Insulin is an anabolic hormone that influences vascular tone in both large calibre conductance vessels and small calibre exchange vessels such as the capillary microcirculation.1,2 In view of the increased burden of cardiovascular disease in patients with diabetes, and the capability of insulin to influence both metabolic and vascular function, insulin therapy has the potential to improve prognosis from cardiovascular disease in patients with diabetes. The metabolic ef

| Full text

July 2009 Br J Cardiol 2009;16:163-6

New NICE guidelines on new treatments for type 2 diabetes

BJCardio editorial staff

Abstract

Summary of therapies and key recommendations are: Insulin therapy (including the long-acting insulin analogues, insulin detemir, insulin glargine) Insulin detemir and insulin glargine, like NPH insulin, provide slowly-released insulin to meet basal requirements.  When the decision to start insulin is made, human NPH insulin should be started; healthcare professionals should consider switching to a long-acting insulin analogue if the patient experiences significant hypoglycaemia, is unable to use the device needed to inject NPH insulin, or needs help to inject the insulin from a carer or healthcare professional, and for whom switching to a lo

| Full text

March 2003 Br J Cardiol 2003;10:128-36

Antidiabetic drugs

Clifford J Bailey, Caroline Day

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now